Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the recipient of a large decline in short interest in the month of March. As of March 31st, there was short interest totalling 105,800 shares, a decline of 9.6% from the March 15th total of 117,100 shares. Based on an average daily trading volume, of 34,600 shares, the days-to-cover ratio is presently 3.1 days. Approximately 2.4% of the company’s shares are sold short.

Aprea Therapeutics Trading Down 3.4 %

Aprea Therapeutics stock opened at $5.70 on Wednesday. Aprea Therapeutics has a twelve month low of $2.78 and a twelve month high of $8.85. The stock’s fifty day simple moving average is $6.52 and its 200-day simple moving average is $5.21. The firm has a market capitalization of $30.95 million, a P/E ratio of -1.43 and a beta of 1.03.

Aprea Therapeutics (NASDAQ:APRE) last posted its quarterly earnings data on Tuesday, March 26th. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.36). The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.33 million. Sell-side analysts predict that Aprea Therapeutics will post -2.38 earnings per share for the current year.

Insider Activity

In other news, Director Bernd R. Seizinger purchased 6,860 shares of Aprea Therapeutics stock in a transaction dated Wednesday, March 13th. The shares were purchased at an average price of $7.29 per share, with a total value of $50,009.40. Following the transaction, the director now owns 33,685 shares in the company, valued at $245,563.65. The purchase was disclosed in a document filed with the SEC, which is available through this link. In the last 90 days, insiders have bought 9,870 shares of company stock valued at $71,952. 20.90% of the stock is currently owned by company insiders.

Institutional Trading of Aprea Therapeutics

A number of large investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Aprea Therapeutics by 26.9% during the fourth quarter. Vanguard Group Inc. now owns 34,688 shares of the company’s stock worth $163,000 after acquiring an additional 7,347 shares during the period. Royal Bank of Canada grew its stake in shares of Aprea Therapeutics by 13,788.0% during the fourth quarter. Royal Bank of Canada now owns 44,025 shares of the company’s stock worth $207,000 after purchasing an additional 43,708 shares in the last quarter. Geode Capital Management LLC acquired a new position in shares of Aprea Therapeutics during the second quarter worth $74,000. Millennium Management LLC grew its stake in shares of Aprea Therapeutics by 35.7% during the fourth quarter. Millennium Management LLC now owns 164,626 shares of the company’s stock worth $53,000 after purchasing an additional 43,293 shares in the last quarter. Finally, BNP Paribas Arbitrage SNC acquired a new position in shares of Aprea Therapeutics during the third quarter worth $40,000. Hedge funds and other institutional investors own 34.19% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Aprea Therapeutics in a research report on Tuesday, March 26th. Wedbush boosted their target price on Aprea Therapeutics from $9.00 to $11.00 and gave the company an “outperform” rating in a research report on Wednesday, March 27th.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers.